Literature DB >> 10733909

Rat receptor-activity-modifying proteins (RAMPs) for adrenomedullin/CGRP receptor: cloning and upregulation in obstructive nephropathy.

T Nagae1, M Mukoyama, A Sugawara, K Mori, K Yahata, M Kasahara, T Suganami, H Makino, Y Fujinaga, T Yoshioka, I Tanaka, K Nakao.   

Abstract

Adrenomedullin (AM) is a potent vasorelaxing peptide originally isolated pheochromocytoma. Recently, a family of receptor-activity-modifying proteins (RAMPs 1-3) were identified in humans. Associated with the calcitonin receptor-like receptor (CRLR), RAMP2 or RAMP3 may function as the AM receptor. Here we cloned rat RAMP family, analyzed their distribution in rat tissues, and examined regulation of their expression in the kidney using an obstructive nephropathy model. Northern blot analyses revealed that the RAMP family genes are expressed in various tissues with different tissue specificity; RAMP1 is abundantly expressed in the brain, fat, thymus, and spleen, RAMP2 in the lung, spleen, fat, and aorta, while RAMP3 is most abundant in the kidney and lung. After ureteral obstruction, RAMP1, RAMP2, and CRLR gene expressions in the obstructed kidney were markedly upregulated, whereas RAMP3 expression was unchanged. Thus, RAMPs are regulated differently in obstructive nephropathy, suggesting their distinct roles in renal pathophysiology. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733909     DOI: 10.1006/bbrc.2000.2390

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  15 in total

Review 1.  The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors.

Authors:  Debbie L Hay; Alex C Conner; Stephen G Howitt; David M Smith; David R Poyner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Receptor activity-modifying protein-1 augments cerebrovascular responses to calcitonin gene-related peptide and inhibits angiotensin II-induced vascular dysfunction.

Authors:  Sophocles Chrissobolis; Zhongming Zhang; Dale A Kinzenbaw; Cynthia M Lynch; Andrew F Russo; Frank M Faraci
Journal:  Stroke       Date:  2010-09-02       Impact factor: 7.914

3.  Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner.

Authors:  Cordelia J Barrick; Patricia M Lenhart; Ryan T Dackor; Elizabeth Nagle; Kathleen M Caron
Journal:  J Mol Cell Cardiol       Date:  2011-11-04       Impact factor: 5.000

Review 4.  Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine.

Authors:  Eric L Moore; Christopher A Salvatore
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 5.  Regulation of endothelial and epithelial barrier functions by peptide hormones of the adrenomedullin family.

Authors:  Alexander García-Ponce; Sandra Chánez Paredes; Karla Fabiola Castro Ochoa; Michael Schnoor
Journal:  Tissue Barriers       Date:  2016-08-25

6.  CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

Authors:  D L Hay; S G Howitt; A C Conner; M Schindler; D M Smith; D R Poyner
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

7.  Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress.

Authors:  Makoto Hagiwara; Grant Bledsoe; Zhi-Rong Yang; Robert S Smith; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

Review 8.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

9.  Receptor activity-modifying protein 1 increases baroreflex sensitivity and attenuates Angiotensin-induced hypertension.

Authors:  Rasna Sabharwal; Zhongming Zhang; Yongjun Lu; Francois M Abboud; Andrew F Russo; Mark W Chapleau
Journal:  Hypertension       Date:  2010-01-25       Impact factor: 10.190

10.  Evidence of a role for NK1 and CGRP receptors in mediating neurogenic vasodilatation in the mouse ear.

Authors:  Andrew D Grant; Norma P Gerard; Susan D Brain
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.